Summer read

Make the most of summer by taking time to recharge and discover what’s new in prostate cancer (PCa) care. Our editorial board has hand-picked a selection of key articles for you. Read on to see our experts’ recommendations on PCa care.

• Learn about the PCWG4, which updates the standards for clinical trial design, incorporating PSMA PET imaging and modern biomarker-based endpoints. This publication will shape future PCa trials and facilitate comparisons across studies.
  Trial design and objectives for patients with prostate cancer: Recommendations from the Prostate Cancer Working Group 4
• Did you know that PRIMARY2 demonstrated that PSMA PET can identify clinically significant prostate cancer in selected men with elevated PSA despite non-suspicious or equivocal prostate MRI?
  Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): A multicentre, non-inferiority, phase 3, randomised controlled trial
• The first trial to demonstrate an overall survival benefit with the addition of metastasis-directed therapy (MDT) to castration-resistant prostate cancer (CRPC) patients is the phase II ARTO trial, which showed an improvement in overall survival (median OS NR vs 50 months, HR 0·55, 95% CI 0·33–0·92, p=0·021) with the addition of MDT to abiraterone acetate and prednisone, in oligometastatic CRPC patients.
  SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): Long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
• Interested in the first individual meta-analysis on the role of MDT for oligometastatic prostate cancer (OMPC)? The WOLVERINE meta-analysis collected individual patient data across trials to evaluate the effectiveness of MDT for OMPC, and showed a benefit with MDT for OMPC in progression-free survival, radiological progression-free survival, and castration resistance-free survival.
  Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): A systematic review and individual patient data meta-analysis from the X-MET collaboration